Besifloxacin (Hydrochloride)

Besifloxacin Hydrochloride is a fourth generation fluoroquinolone antibiotic. Besifloxacin Hydrochloride is a DNA gyrase and topoisomerase IV inhibitor. Besifloxacin Hydrochloride has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research[1][2][3][4].

Product Specifications

CAS Number

[405165-61-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial; DNA/RNA Synthesis; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/besifloxacin-hydrochloride.html

Purity

98.49

Solubility

DMSO : < 1 mg/mL|Ethanol : < 1 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL

Smiles

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@H](N)CCCC4)=C3Cl)C1=O)O.[H]Cl

Molecular Formula

C19H22Cl2FN3O3

Molecular Weight

430.30

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhang JZ, et al. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008 Jan;61 (1) :111-6.|[2]Sanfilippo CM, et al. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin. Chemotherapy. 2011;57 (5) :363-71.|[3]Haas W, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009 Aug;53 (8) :3552-60.|[4]Sanders ME, et al. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. J Ocul Pharmacol Ther. 2010 Apr;26 (2) :193-8.